The new technology of robotic surgery system, as an emerging technology, has shown certain application prospects in breast surgery. However, the new technology of robotic surgery system in China in the treatment of gynecomastia is still in the exploratory stage and needs to be further improved. This prospective, single-center, single-arm clinical study was conducted to use the single-port robot and evaluate the effectiveness and safety of the subcutaneous gland resection in the treatment of gynecomastia.
Male patients, aged 18-75 years old;
Preoperative breast ultrasound indicates male breast development, and breast enlargement symptoms persist for more than 1 year;
Primary male breast development that has been unresponsive to drug treatment, or those who refuse drug treatment;
According to Gynecomastia's surgical indications, refer to the "2023 Expert consensus on the clinicaldiagnosis and treatment of gynecomastia in China" Simon grading of male breast development IIb or above;
Age<16 years old, still in puberty, or disease duration ≤ 1 year;
Simple obesity, no obvious glandular tissue was found on breast ultrasound examination;
Male patients with breast developmental disorders secondary to other diseases;
Patients with contraindications for general anesthesia surgery such as coagulation dysfunction and severe cardiovascular disease, who cannot tolerate surgery;